CSIMarket
 


Recursion Pharmaceuticals Inc   (RXRX)
Other Ticker:  
 
 

RXRX's Operating Income Growth by Quarter and Year

Recursion Pharmaceuticals Inc 's Operating Income results by quarter and year




RXRX Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -98.93 -60.98 -64.96 0.00
III Quarter September -99.55 -62.57 -46.40 0.00
II Quarter June -81.72 -66.19 -40.93 0.00
I Quarter March -69.87 -55.98 -30.48 0.00
FY   -350.07 -245.72 -182.77 0.00



RXRX Operating Income fourth quarter 2023 Y/Y Growth Comment
Recursion Pharmaceuticals Inc in the fourth quarter 2023 recorded Operating Loss of $ -98.93 millions.

According to the results reported in the fourth quarter 2023, Recursion Pharmaceuticals Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Recursion Pharmaceuticals Inc ' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2023.

Explain Operating Income growth


RXRX Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Recursion Pharmaceuticals Inc 's fourth quarter 2023 Operating Income $ -98.93 millions RXRX's Income Statement
Recursion Pharmaceuticals Inc 's fourth quarter 2022 Operating Income $ -60.98 millions Quarterly RXRX's Income Statement
New: More RXRX's historic Operating Income Growth >>


RXRX Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Recursion Pharmaceuticals Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RXRX's IV. Quarter Q/Q Operating Income Comment
Despite the fact, that Recursion Pharmaceuticals Inc in the IV. Quarter 2023 showed Operating Loss of $ -98.93 millions, some analyst mentioned, that those numbers are improvement in contrast to the -99.55 millions in the third quarter.

Within Biotechnology & Pharmaceuticals industry Recursion Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Recursion Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RXRX's IV. Quarter Q/Q Operating Income Comment
Even if Recursion Pharmaceuticals Inc in the IV. Quarter 2023 admitted Operating Loss of $ -98.93 millions, it should be point out, that those numbers show improvement relative to the -99.55 millions in the third quarter.

Within Biotechnology & Pharmaceuticals industry Recursion Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Recursion Pharmaceuticals Inc 's Operating Income growth quarter on quarter, overall rank is .


Recursion Pharmaceuticals Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Operating Income 12 Months Ending $ -350.06 $ -312.11 $ -275.14 $ -259.61 $ -245.73
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Recursion Pharmaceuticals Inc ' has realized cumulative trailing twelve months Operating Loss of $ -350 millions in the Dec 31 2023 period.
The business is getting worse as the cumulative Operating Loss is becoming larger from $ -312.11 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -249.705 millions for the twelve months ending in the quarter a year ago.

Recursion Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Recursion Pharmaceuticals Inc ' has realized cumulative trailing twelve months Operating Loss of $ -350 millions in the Dec 31 2023 period.
The business is worsening as the cumulative Operating Loss is becoming larger from $ -312.11 millions in the twelve months ending a quarter before and $ -249.705 millions for the twelve months ending in the quarter a year ago.

Recursion Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
RXRX's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for RXRX's Competitors
Operating Income Growth for Recursion Pharmaceuticals Inc 's Suppliers
Operating Income Growth for RXRX's Customers

You may also want to know
RXRX's Annual Growth Rates RXRX's Profitability Ratios RXRX's Asset Turnover Ratio RXRX's Dividend Growth
RXRX's Roe RXRX's Valuation Ratios RXRX's Financial Strength Ratios RXRX's Dividend Payout Ratio
RXRX's Roa RXRX's Inventory Turnover Ratio RXRX's Growth Rates RXRX's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2023
Quest Diagnostics Inc97.78%$ 97.778 millions
3m Company96.68%$ 96.677 millions
Elite Pharmaceuticals Inc 80.32%$ 80.320 millions
Dr Reddy s Laboratories Limited78.66%$ 78.663 millions
Electromed Inc 77.63%$ 77.630 millions
Eli Lilly And Company74.93%$ 74.935 millions
Dexcom Inc 72.97%$ 72.967 millions
Sotera Health Company72.89%$ 72.889 millions
Alcon inc 54.61%$ 54.613 millions
Stryker Corp54.42%$ 54.423 millions
Align Technology inc 52.27%$ 52.267 millions
Davita Inc 52.16%$ 52.158 millions
Healthcare Services Group Inc 51.40%$ 51.399 millions
Tactile Systems Technology Inc 50.32%$ 50.318 millions
Viemed Healthcare Inc 49.66%$ 49.660 millions
United Therapeutics Corporation48.12%$ 48.121 millions
Lemaitre Vascular Inc 46.49%$ 46.491 millions
Neurocrine Biosciences Inc 45.36%$ 45.358 millions
Boston Scientific Corporation45.27%$ 45.274 millions
Msa Safety Incorporated44.79%$ 44.789 millions
Corcept Therapeutics Inc40.76%$ 40.757 millions
Powerup Acquisition Corp 39.00%$ 38.999 millions
Tenet Healthcare Corp37.13%$ 37.127 millions
Chemed Corporation36.97%$ 36.971 millions
Abbott Laboratories36.50%$ 36.503 millions
Nature s Sunshine Products inc 36.49%$ 36.490 millions
Halozyme Therapeutics Inc 35.60%$ 35.601 millions
Catalyst Pharmaceuticals Inc 35.36%$ 35.359 millions
Iqvia Holdings Inc 32.19%$ 32.190 millions
Select Medical Holdings Corp31.53%$ 31.531 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com